FDA Watch: CND Life Sciences Wins Breakthrough Device Designation for Skin-Based Neurodegenerative Test
The Syn-One assay can diagnose multiple conditions without needing a lumbar puncture
Author Information
Ron Shinkman
Ron Shinkman is a veteran journalist and editor with more than 20 years of experience in the healthcare business realm. He served as Los Angeles bureau chief of Modern Healthcare and also wrote for the Los Angeles and Orange County Business Journals.
Posts by the Author
Dx Deals: Labcorp and Roche Enter into Pacts to Distribute Alzheimer’s Tests, Digitize Slides
The technology developed by Roche in recent years seems a good fit for Labcorp’s testing services
Diagnostic Pipeline: Labcorp Uses Chewing Gum Samples to Identify Bone Marrow Donors
The initiative is in conjunction with The Gift of Life registry and Doublemint Gum
Dx Deals: Sonic Healthcare Buys East Coast Lab in First Such US Acquisition Since 2021
Australian firm has grown its overseas operations dramatically in the past decade, except in America
FDA Watch: Mass Spectrometry Test Receives First Moderate Complexity Designation
Roche’s vitamin D assay includes internal quality controls that allowed it to obtain the CLIA designation
National Lab Companies Move Quickly to Market Fujirebio’s Lumipulse for Earlier Alzheimer’s Detection
The new blood-based assay avoids painful lumbar punctures and may quicken Alzheimer’s diagnoses
Diagnostics Pipeline: Postpartum Lab Panel Launched by Trellis Health
The intent of the at-home testing is to identify and treat issues such as postpartum depression and vitamin deficiencies
Dx Deals: Corewell Health Enters Joint Venture with Quest Diagnostics
The lab giant and the Michigan health system will build a 100,000-square-foot lab as part of a new business
FDA Watch: BD Receives FDA Approval for Veritor, a Pandemic Staple
The assay was widely used during the early months of COVID-19 and was a significant source of revenue growth for a time
Dx Deals: Illumina to Acquire SomaLogic from Standard BioTools for $425M
The deal is expected to be a big boost for Illumina’s next-generation sequencing platforms
